Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
No one on the platform currently holds IMGN.
No tracked institution reports a position in IMGN as of their last filing.
No one on the platform has traded IMGN yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$IOVA $IMGN was brought out after a good earning that pop it to $12 and buyout at $30..
View on StockTwits ↗
$SLS So many inch thick, who think they know it all, and actually Know Very Little... Just the Secondary Asset - already published Phase 2 Expansion Data for AML-MR Patients, the most dire AML Prognosis, that is Better than P1B $IMGN Magrolimab AML-MR data that got bought for $5B // $24 Per SLS Share ...
View on StockTwits ↗$SLS $MRK GPS Keytruda Phase 2 MOS for Platinum Resistant/Refractory Ovarian Cancer was 18.4 months / 75% Refractory. These results in end stage OC, are better than the 16.46 Month MOS Elahere $IMGN Achieved, that earned FDA Approval and a $10B Buyout buy $ABBV. $MRK Dr. Cohen concluded in co-authoring the publication, that GPs + Key would work even Better in a Macroscopic (remission Setting). Merck has been Waiting for Gps Phase 3 Results / Like all of Us Expecting them last year - before they are willing to Pay Angies Max Value ... Just GPs +Key in PR/ROC is worth $10B to MRK / or BMY
View on StockTwits ↗
$MRK is just waiting, like all of us for the imminent Gps p3 trial results before buying SLS Gps and Pembro results in PROC is better than Elahere $IMGN which got fda approved and bought for 16.4 months $ABBV https://www.biospace.com/sellas-life-sciences-presents-positive-key-immunobiological-and-clinical-data-from-phase-1-2-trial-of-galinpepimut-s-gps-in-combination-with-keytruda-in-wt1-platinum-resistant-advanced-ovarian-cancer-at-the-igcs-2023-annual-global-meeting
View on StockTwits ↗
$SLS can't wait till this board looks like $IMGN
View on StockTwits ↗$SLS 196M Shares Float / $80 Per SLS Share is only $15.6B and that is Less than Half what Big Pharma will be Buying SLS For... as others have pointed out many times, there have been and are No Job Openings at SLS --- 13 FTE ' s and an IMMINENT P3 Result - NO Hiring --- Does Everyone recall, Angie stating they have had ongoing Contacts with multiple Pharma's, and that he would Update the public when he has something Concrete. $MRK Knows GPS is worth at Least 10B just for PR/ROC and MESO TERM Sheets are already ready for Ink - Just waiting on the P3 Results. - Elahere $IMGN achieved a MOS of 16.46 months for Pr/ROC and was bought by $ABBV for $10.1B - GPS +Keytruda achieved a Phase 1/2 MOS Result of 18.4 Months in the same exact patient setting. Gps Extends Patent Life for $KEYTRUDA or $OPDIVO for another 10 YEARS
View on StockTwits ↗pardon -- that was the $IMGN Chart - the day before they released P3 data - the market hammered the share price.
View on StockTwits ↗$IMGN $SLS Be Holding when the 80th EVENT PR is ANNOUNCED. Expect a 2x 3x+ Move and the share Price will continue CLIMBING. Gps is truly worth Several Tens of billions to big Pharma. -- discussion regarding GPS WT1 Value -- Gps + Pembro/Keytruda Phase 2 Trial Results - achieved Longer Survival for PR/ROC Patients than Elahere/ $IMGN which $ABBV bought for $10.1B Elahere MOS of 16.46 MONTHS / GPS Key 18.4 MONTHS. - Just this 1 Direct Market Comp at $10B GPS is worth Tens of Billions to big Pharma. Even the $MRK Dr. co-authoring the Final P2 DATA, stated Gps warranted further P3 Trials, - this is a massively bullish in Medspeak.
View on StockTwits ↗
$ABBV $IMGN $LLY $PFE $SLS Volume just crossed 5 million shares in first 2.5 hours of trading. Big Institutional funds gobbling up every loose share before the next PR Hits. ✌️❤️🩹🙏
View on StockTwits ↗$IMGN $LLY $PFE $SLS $ABBV AbbVie will make a move before the bidding war starts. I see them coming before the GPS Regal Pivotal Registrational phase 3 data comes out. Ventoclax is $1.9 Billion dollar annual blockbuster for AbbVie. Merck has already done multiple studies with SLS GPS+ Keytruda, with Keytruda patent expiring in 2028. Merck will be part of the bidding war unless AbbVie picks them up pre data read out! ✌️❤️🩹🙏
View on StockTwits ↗$IMGN $LLY $PFE $SLS Greg, PFE is # 1 suitor on my list followed by AbbVie. AbbVie Ventoclax will be Obsolete after GPS approval. Pfizer has made all the moves and CEO Dr. Bourla is a close friend of Sellas CEO Dr. Angelos Stergiou. 👇✌️❤️🩹🙏
View on StockTwits ↗$SLS $LLY $PFE CEO Explaining approximately 12,000 AML CR2 patients will be Eligible for GPS Immunotherapy each year EU/US/J. xCCO estimated Minimum Pricing comps of $280K / $300K Rev Per Patient Year 1 Infinite Dosing Regime - Year 2 $110K Rev. - Just AMLCR2/3 is worth Nearly $75 Per Share to Big Pharma and You can't have any CR2/3 Value without Applying further Value for CR1 / Post Stem Cell Transplant, + MESO and PRROC. - GPS +Keytruda Phase 2 PR/ROC MOS of 18.4 Months was better than Elahere $IMGN that got bought for $10.1B ... as a single comp.
View on StockTwits ↗$SLS 125 Million+ Cash on hand per last 10K filing. Gps will be CURATIVE in over 20+ WT1 cancer Types. GPS Ad Infinitum Dosing will generate over $50 Billion+ annually for Big Pharmaceutical Suitors. GPs has already proven effective in Mesothelioma and Platinum Resistant Ovarian Cancer settings, achieving better Phase 2 Combination trial Results with Keytruda $MRK - MOS of 18.4 months - than, Elahere $IMGN 16.4 Months, which earned FDA Approval and was bought by $ABBV for $10.1B - this is just 1 comp worth $10B. SLS009 has already shown 4 times better response in phase 2b than current SOC. Bidding war is coming $280 Per share. Don’t step over hundred dollar 💵 Bills to pick up Pennie’s. Hold with Conviction. ✌️🙏❤️🩹
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.